Skip to main content

Pfizer Inc third-quarter 2004 performance report

Pressmeddelande   •   Okt 20, 2004 13:57 CEST

Third-Quarter Adjusted Income' Grows 13 Percent
to $4.160 Billion; Third-Quarter Adjusted Diluted EPS'
Up 15 Percent to $.55
Estimate of Full-Year 2004 Adjusted Diluted EPS*
of $2.12-$2.14 Reconfirmed
Third-Quarter Reported Net Income of $3.341 Billion;
Third-Quarter Reported Diluted EPS of $.44
Quarterly Revenues Increase 4 Percent to $12.831 Billion;
Lipitor and COX-2 Products Achieve Strong Growth
Quarter Marked by FDA-Approved Inclusion of ASCOT-LLA Data in
Lipitor and Caduet Labeling, E.U. Approval of Lyrica for Epilepsy
and Neuropathic Pain, U.S. Approval of Geodon for Bipolar Mania,
U.S. Filing of Lasofoxifene for Osteoporosis Prevention,
Initial Enrollment in Pfizer Helpful Answers Program
Revenue and Income Growth in 2005 to Be Tempered
by Patent Expirations and Other Factors;
Longer-Term Growth Prospects Remain Strong
Pfizer Remains On Track to Submit an Industry-Record
20 Major U.S. Regulatory Filings in 2001-2006


Full report and additional information, click here.

Audio Webcast — Conference Call for Analysts and Investors
Wednesday, October 20, 2004 2:30 PM EDT


* "Adjusted income" and "adjusted diluted earnings per share (EPS)" are defined as reported net income and reported diluted earnings per share excluding discontinued operations, the cumulative effect of a change in accounting principle, significant impacts of purchase accounting for acquisitions, merger-related costs, and certain significant items. A reconciliation to reported net income and reported diluted EPS is provided within this document.

Pfizer är världens ledande läkemedelsföretag. Vi satsar stora resurser på forskning och på samarbeten med olika parter för att bidra till framtidens hälso- och sjukvård. Pfizer har läkemedel inom de flesta terapiområden. I Sverige finns produktion samt omfattande klinisk forskning.